Evidence map›Paper›PMID 39320960›Full record

Trial reportClinical and translational gastroenterology2024

Intravenous Lidocaine for Refractory Pain in Patients With Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis: A Multicenter Prospective Nonrandomized Pilot Study.

Simone Augustinus, Matthanja Bieze, Charlotte L Van Veldhuisen, Marja A Boermeester, Bert A Bonsing, Stefan A W Bouwense, Marco J Bruno, Olivier R Busch, Werner Ten Hoope, Jan-Willem Kallewaard and 13 more

Abstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. 16. Pain in chronic pancreatitis.Pain practice : the official journal of World Institute of Pain · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Simone AugustinusAmsterdam UMC, University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.ORCID 0000-0002-0625-4349
Matthanja BiezeAmsterdam UMC, University of Amsterdam, Department of Anesthesiology, Amsterdam, the Netherlands.
Charlotte L Van VeldhuisenAmsterdam UMC, University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Marja A BoermeesterAmsterdam UMC, University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Bert A BonsingDepartment of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Stefan A W BouwenseDepartment of Surgery, Maastricht Universitair Medisch Centrum+, Maastricht, the Netherlands.
Marco J BrunoDepartment of Gastroenterology & Hepatology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Olivier R BuschAmsterdam UMC, University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Werner Ten HoopeDepartment of Anesthesiology, Rijnstate Ziekenhuis, Arnhem, the Netherlands.
Jan-Willem KallewaardAmsterdam UMC, University of Amsterdam, Department of Anesthesiology, Amsterdam, the Netherlands.
Henk J van KranenInspire2live, Houten, the Netherlands.
Marieke NiestersDepartment of Anesthesiology, Leiden University Medical Center, Leiden, the Netherlands.
Niels C J SchellekensAmsterdam UMC, University of Amsterdam, Department of Anesthesiology, Amsterdam, the Netherlands.
Monique A H SteegersAmsterdam UMC, University of Amsterdam, Department of Anesthesiology, Amsterdam, the Netherlands.
Rogier P VoermansAmsterdam UMC, University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, the Netherlands.
Judith de Vos-GeelenDepartment of Medical Oncology, GROW, Maastricht University Medical Center+, Maastricht, the Netherlands.
Johanna W WilminkCancer Center Amsterdam, Amsterdam, the Netherlands.
Jan H M Van ZundertDepartment of Anesthesiology and Pain Medicine, Maastricht Universitair Medisch Centrum+, Maastricht, the Netherlands.
Casper H van EijckDepartment of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands .
Marc G BesselinkAmsterdam UMC, University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Markus W HollmannAmsterdam UMC, University of Amsterdam, Department of Anesthesiology, Amsterdam, the Netherlands.
Dutch Pancreatic Cancer Group
Dutch Pancreatitis Study Group

Funding

Inspire2Live, Deltaplan Alveesklierkanker WOO 22-01
6 · The paper itself

Abstract

introductionRefractory pain is a major clinical problem in patients with pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP). New, effective therapies to reduce pain are urgently needed. Intravenous lidocaine is used in clinical practice in patients with PDAC and CP, but its efficacy has not been studied prospectively.

methodsMulticenter prospective nonrandomized pilot study included patients with moderate or severe pain (Numeric Rating Scale ≥ 4) associated with PDAC or CP in 5 Dutch centers. An intravenous lidocaine bolus of 1.5 mg/kg was followed by continuous infusion at 1.5 mg/kg/hr. The dose was raised every 15 minutes until treatment response (up to a maximum 2 mg/kg/hr) and consecutively administered for 2 hours. Primary outcome was the mean difference in pain severity, preinfusion, and the first day after (Brief Pain Inventory [BPI] scale 1-10). A BPI decrease ≥1.3 points was considered clinically relevant.

resultsOverall, 30 patients were included, 19 with PDAC (63%) and 11 with CP (37%). The mean difference in BPI at day 1 was 1.1 (SD ± 1.3) points for patients with PDAC and 0.5 (SD ± 1.7) for patients with CP. A clinically relevant decrease in BPI on day 1 was reported in 9 of 29 patients (31%), and this response lasted up to 1 month. No serious complications were reported, and only 3 minor complications (vertigo, nausea, and tingling of mouth). Treatment with lidocaine did not impact quality of life. DISCUSSION: Intravenous lidocaine in patients with painful PDAC and CP did not show an overall clinically relevant reduction of pain. However, this pilot study shows that the treatment is feasible in this patient group and had a positive effect in a third of patients which lasted up to a month with only minor side effects. To prove or exclude the efficacy of intravenous lidocaine, the study should be performed in a study with a greater sample size and less heterogeneous patient group.

Indexed as

Anesthetics, LocalCarcinoma, Pancreatic DuctalIntractable PainLidocainePain MeasurementPancreatic NeoplasmsPancreatitis, ChronicAdultAgedFemaleHumansInfusions, IntravenousMaleMiddle AgedNetherlandsPilot ProjectsAnesthetics, LocalLidocaine

Identifiers

PMID39320960
PMCPMC11421722

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.